DocCheck AG (AJ91) AI Stock Analysis

3 Followers

DocCheck AG

(XETRA:AJ91)

Select Model

Rating:63Neutral

Price Target:EUR 11.50▲(10.58% Upside)

Action:reiterated

Date:08/22/26

The score is driven primarily by solid financial stability (low leverage and healthy equity base) but tempered by weaker operating momentum and inconsistent cash-flow conversion. Valuation is a meaningful positive (moderate P/E and high dividend yield), while technical indicators are clearly bearish with the stock trading below key moving averages and negative MACD.

Positive Factors

Conservative Balance SheetLow leverage and a strong equity base reduce financial risk and preserve flexibility for investment, dividends, or resilience if healthcare-sector marketing demand weakens.

Negative Factors

Weak Revenue TrajectoryRecent revenue contraction indicates weaker demand or execution momentum, limiting operating leverage and making sustained earnings growth less dependable over the next several reporting periods.

DocCheck AG (AJ91) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 52.77M
Dividend Yield: 9.62%
Average Volume (3M): 380
Price to Earnings (P/E): 11.3
Beta (1Y): 0.44
Revenue Growth: 1.35%
EPS Growth: -20.52%
Country: Germany
Employees: 414
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Distribution

DocCheck AG Business Overview & Revenue Model

Company Description

DocCheck AG offers community, agency, and e-commerce services for the healthcare sector in Europe. The company develops and implements communication strategies for media on healthcare and business-to-business sectors; sells medical supplies and medic...

How the Company Makes Money

DocCheck AG primarily generates revenue by selling digital marketing, communication, and related online services to customers in the healthcare and life-sciences industry, using its healthcare-professional-focused online environment and audience acce...

DocCheck AG Financial Statement Overview

Summary

Financially stable with a conservative balance sheet (Balance Sheet Score 78; low leverage and solid equity base), but operating performance and cash conversion are less reliable. Profitability remains healthy (Income Statement Score 62) despite weaker growth and 2025 revenue decline, while cash-flow quality is a key concern (Cash Flow Score 55) given volatile free cash flow and weaker conversion vs. net income in 2025.

Income Statement

62Positive

Balance Sheet

78Positive

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	56.65M	55.32M	53.79M	53.41M	60.90M	85.92M
Gross Profit	10.57M	12.28M	10.53M	12.97M	14.08M	21.54M
EBITDA	10.02M	10.39M	10.18M	9.38M	13.38M	20.09M
Net Income	4.66M	5.33M	5.28M	2.27M	6.29M	11.40M
Balance Sheet
Total Assets	53.40M	55.68M	60.86M	56.14M	63.28M	60.25M
Cash, Cash Equivalents and Short-Term Investments	15.98M	18.54M	21.02M	17.52M	15.66M	21.52M
Total Debt	2.76M	4.16M	5.01M	5.85M	7.07M	7.03M
Total Liabilities	15.08M	14.07M	20.78M	18.11M	23.86M	22.08M
Stockholders Equity	38.32M	41.61M	40.08M	37.33M	38.57M	37.31M
Cash Flow
Free Cash Flow	1.52M	2.61M	6.82M	5.62M	-557.91K	6.90M
Operating Cash Flow	5.26M	6.14M	7.82M	7.51M	5.89M	10.92M
Investing Cash Flow	-2.65M	-3.81M	-1.48M	-1.93M	-4.92M	-4.39M
Financing Cash Flow	-6.07M	-4.88M	-3.50M	-4.60M	-5.81M	-5.86M

DocCheck AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:AJ91 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:AJ91	63Neutral	EUR 52.77M	11.30	11.67%	9.62%	1.35%	-20.52%
DE:ILM1	59Neutral	EUR 277.50M	24.73	2.16%	―	8.40%	-61.68%
DE:M3V	55Neutral	EUR 36.40M	26.32	7.77%	4.75%	-6.92%	-67.82%
DE:COP	53Neutral	EUR 1.49B	43.42	4.19%	1.75%	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:AJ91 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:AJ91	DocCheck AG	10.40	-0.72	-6.45%
DE:COP	CompuGroup Medical	28.20	5.02	21.64%
DE:M3V	MeVis Medical Solutions	20.00	-3.90	-16.32%
DE:ILM1	Medios AG	10.88	-3.42	-23.92%
DE:MDQ	MediNavi AG	3.80	-0.20	-5.00%
DE:5NB	Novetum AG	42.00	13.40	46.85%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 22, 2026

DocCheck AG AI Stock Analysis